GABAergic function in Alzheimer's disease: evidence for dysfunction and potential as a therapeutic target for the treatment of behavioural and psychological symptoms of dementia.
about
An immunohistochemical study of GABA A receptor gamma subunits in Alzheimer's disease hippocampus: relationship to neurofibrillary tangle progressionDrug Development in Alzheimer's Disease: The Contribution of PET and SPECTCan zebrafish be used as animal model to study Alzheimer's disease?Brain type carnosinase in dementia: a pilot study.Role of Sleep Disturbance in the Trajectory of Alzheimer's Disease.Transgenic autoinhibition of p21-activated kinase exacerbates synaptic impairments and fronto-dependent behavioral deficits in an animal model of Alzheimer's disease.Decreased γ-aminobutyric acid levels in the parietal region of patients with Alzheimer's disease.Risk of dementia in patients with insomnia and long-term use of hypnotics: a population-based retrospective cohort study.Anterior insula GABA levels correlate with emotional aspects of empathy: a proton magnetic resonance spectroscopy study.Hippocampal interneuron loss in an APP/PS1 double mutant mouse and in Alzheimer's disease.Alzheimer's-type amyloidosis in transgenic mice impairs survival of newborn neurons derived from adult hippocampal neurogenesis.Loss of functional GABA(A) receptors in the Alzheimer diseased brain.Spatial variability and reproducibility of GABA-edited MEGA-LASER 3D-MRSI in the brain at 3 T.Genetic Influences on Plasma Homocysteine Levels in African Americans and Yoruba NigeriansPharmacologic management of neuropsychiatric symptoms of Alzheimer disease.Behavioural genetics of Alzheimer's disease: a comprehensive review.GABAergic neurotransmission and new strategies of neuromodulation to compensate synaptic dysfunction in early stages of Alzheimer's disease.Non human primate models for Alzheimer's disease-related research and drug discovery.Posterior cingulate γ-aminobutyric acid and glutamate/glutamine are reduced in amnestic mild cognitive impairment and are unrelated to amyloid deposition and apolipoprotein E genotype.Towards a Better Understanding of GABAergic Remodeling in Alzheimer's Disease.Antipsychotics in Alzheimer's disease: A critical analysis.Evaluation of Metabolic and Synaptic Dysfunction Hypotheses of Alzheimer's Disease (AD): A Meta-Analysis of CSF Markers.Ghrelin Causes a Decline in GABA Release by Reducing Fatty Acid Oxidation in Cortex.Control of N-Heterocyclic Carbene Catalyzed Reactions of Enals: Asymmetric Synthesis of Oxindole-γ-Amino Acid Derivatives.Amyloid-Beta and Phosphorylated Tau Accumulations Cause Abnormalities at Synapses of Alzheimer's disease Neurons.Effects of chronic noise exposure on the microbiome-gut-brain axis in senescence-accelerated prone mice: implications for Alzheimer's disease.
P2860
Q24613146-612C30C9-F145-4855-9E9F-F6AC0D4FCEBCQ26749755-73D0C110-8446-42BB-AE54-4A39C41DC48EQ30458465-6D0063C3-4C72-4B7F-A4CB-6C08F2EEC86BQ33305023-17EF83EA-C8F2-48FF-9CF9-6C7CF4000002Q33662885-5D59D695-B430-48FA-864C-9470AE29FB0BQ33804587-1568A508-3E9B-43A4-A1AB-94C7F810A1E5Q33907438-7A9D493D-F6A4-4C60-9E57-B77762A85782Q34474081-59EDE7B0-0215-4439-B199-32F43C853F01Q34566476-444147B3-C180-4238-ABC1-162265AA7F2BQ34571233-48E47D9D-2A4C-4AD3-BCAB-482AEC8DFDE8Q35629399-7330E233-9B6C-4FAA-9AA0-AE88ACFF1889Q36056348-D3ED897C-1F81-48EF-8054-50B64480ADF8Q36157848-91D1C617-0334-4C36-A03C-38E91AF484AFQ36770198-A94A43A6-397B-4A22-AD09-C0BFAE669EA7Q37004363-8B6E2182-5141-4F34-BE93-F5F0EB154B57Q37980139-4C011E59-3C8E-449A-B990-F058D4AD158BQ38225536-6DA99CF2-0F20-4337-8C89-47201E0A8D91Q38783343-E333E9F7-329D-41D0-BAF4-AE46858E7979Q41151004-FB67235B-04E7-46D8-999D-83E3F52C5827Q41574564-503CF6E0-FFD7-4C84-A35A-E3D78C89218CQ47101962-02E5F0F4-FA99-49C5-AF65-65C50C837C10Q47937645-EDE1E32E-6C3E-4ACC-9D6B-9B638DC0DCD4Q48112232-6FCFC47F-3181-4745-8A7E-772CB8CA29D4Q48280883-A5E87ED0-53E5-4990-A384-0B6645284545Q49256155-A3100B9E-A9F3-4F74-86BB-7050819C12AFQ55442741-A675FDA6-333F-4AF8-AA7F-CA9B1365C2A1
P2860
GABAergic function in Alzheimer's disease: evidence for dysfunction and potential as a therapeutic target for the treatment of behavioural and psychological symptoms of dementia.
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
2004年论文
@zh
2004年论文
@zh-cn
name
GABAergic function in Alzheime ...... ological symptoms of dementia.
@ast
GABAergic function in Alzheime ...... ological symptoms of dementia.
@en
type
label
GABAergic function in Alzheime ...... ological symptoms of dementia.
@ast
GABAergic function in Alzheime ...... ological symptoms of dementia.
@en
prefLabel
GABAergic function in Alzheime ...... ological symptoms of dementia.
@ast
GABAergic function in Alzheime ...... ological symptoms of dementia.
@en
P2093
P2860
P1476
GABAergic function in Alzheime ...... ological symptoms of dementia.
@en
P2093
Lyla R Khan
Nathan Herrmann
Neil Ingber
Paolo Mazzotta
P2860
P304
P356
10.1177/070674370404900705
P407
P577
2004-07-01T00:00:00Z